Search - tctmd.com

Displaying 141 - 160 of 304

Sort: Relevancy | Date

News Conference News AHA 2020

No Doctor? No Problem: Remote, Pharmacist-Led Intervention Cuts CVD Risk

Michael O'Riordan

November 19, 2020

News Conference News AHA 2020

OMEMI: Omega-3 Fatty Acids No Help in Elderly MI Patients

Todd Neale

November 15, 2020

News Conference News AHA 2020

Statin Benefits Confirmed in Elderly, Along With Harmful Effects of High Cholesterol

Michael O'Riordan

November 12, 2020

News Conference News EAS 2020

Just One-Third of European Patients Get to LDL Cholesterol Goals

Michael O'Riordan

October 13, 2020

News Conference News EAS 2020

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Michael O'Riordan

October 08, 2020

News Daily News

LDL Cholesterol Control Post-PCI Is Low and Linked to Worse Outcomes

Yael L. Maxwell

September 14, 2020

News Daily News

CV Prevention Meds Underused in Hispanic, Latinx PAD Patients

L.A. McKeown

August 12, 2020

News Daily News

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

Michael O'Riordan

August 11, 2020

News Daily News

Cholesterol Guidelines Fail Young MI Patients Who Might Have Benefited From Statins

L.A. McKeown

August 04, 2020

News Daily News

Rosuvastatin-Canagliflozin Combo May Be Toxic, Case Suggests

Todd Neale

August 03, 2020

News Daily News

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

Michael O'Riordan

July 08, 2020

News Daily News

Obesity’s Role in COVID-19 Deaths: Big Food, Slow Government to Blame?

Shelley Wood

June 11, 2020

News Daily News

AHA: Increased Diabetes, CVD Risk for American Indians, Alaskan Natives

Yael L. Maxwell

May 29, 2020

News Daily News

US Poverty Drives CVD in Low-Income Adults Beyond Traditional Risk Factors

L.A. McKeown

May 28, 2020

News Daily News

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

Todd Neale

May 06, 2020

News Daily News

Different Markers of Dyslipidemia Could Help Fine-tune CVD Prevention

Yael L. Maxwell

April 28, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

News Daily News

Long-term Evolocumab Safe, Effective for Familial Hypercholesterolemia Treatment

Yael L. Maxwell

February 12, 2020

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

Advertisement

No Doctor? No Problem: Remote, Pharmacist-Led Intervention Cuts CVD Risk

OMEMI: Omega-3 Fatty Acids No Help in Elderly MI Patients

Statin Benefits Confirmed in Elderly, Along With Harmful Effects of High Cholesterol

Just One-Third of European Patients Get to LDL Cholesterol Goals

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

LDL Cholesterol Control Post-PCI Is Low and Linked to Worse Outcomes

CV Prevention Meds Underused in Hispanic, Latinx PAD Patients

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

Cholesterol Guidelines Fail Young MI Patients Who Might Have Benefited From Statins

Rosuvastatin-Canagliflozin Combo May Be Toxic, Case Suggests

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

Obesity’s Role in COVID-19 Deaths: Big Food, Slow Government to Blame?

AHA: Increased Diabetes, CVD Risk for American Indians, Alaskan Natives

US Poverty Drives CVD in Low-Income Adults Beyond Traditional Risk Factors

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

Different Markers of Dyslipidemia Could Help Fine-tune CVD Prevention

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Long-term Evolocumab Safe, Effective for Familial Hypercholesterolemia Treatment

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content